Markus Otto

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9227551/publications.pdf

Version: 2024-02-01

		7672	17373
393	21,867	79	126
papers	citations	h-index	g-index

427	427	427	21692
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia. Brain, 2023, 146, 321-336.	3.7	30
2	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
3	FRONTotemporal dementia Incidence European Research Studyâ€"FRONTIERS: Rationale and design. Alzheimer's and Dementia, 2022, 18, 498-506.	0.4	12
4	Comparison of clinical rating scales in genetic frontotemporal dementia within the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 158-168.	0.9	7
5	Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 68-74.	0.9	39
6	Practice effects in genetic frontotemporal dementia and at-risk individuals: a GENFI study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 336-339.	0.9	1
7	Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration. Journal of Neural Transmission, 2022, 129, 207-230.	1.4	26
8	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	3.7	27
9	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp>: A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	2.8	21
10	Infantile SOD1 deficiency syndrome caused by a homozygous SOD1 variant with absence of enzyme activity. Brain, 2022, 145, 872-878.	3.7	10
11	Surfactant Protein-G in Wildtype and 3xTg-AD Mice: Localization in the Forebrain, Age-Dependent Hippocampal Dot-like Deposits and Brain Content. Biomolecules, 2022, 12, 96.	1.8	3
12	Utility of the Repeat and Point Test for Subtyping Patients With Primary Progressive Aphasia. Alzheimer Disease and Associated Disorders, 2022, Publish Ahead of Print, .	0.6	1
13	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
14	An Automated Toolbox to Predict Single Subject Atrophy in Presymptomatic Granulin Mutation Carriers. Journal of Alzheimer's Disease, 2022, , 1-14.	1.2	3
15	Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1664.	1.8	11
16	A one-year longitudinal evaluation of cerebrospinal fluid and blood neurochemical markers in a patient with cryptococcal meningitis complicated by ischemic stroke.. Journal of the Neurological Sciences, 2022, 432, 120090.	0.3	3
17	Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 422-435.	0.9	22
18	Blood Î²-Synuclein and Neurofilament Light Chain During the Course of Prion Disease. Neurology, 2022, , 10.1212/WNL.0000000000200002.	1.5	11

#	Article	IF	Citations
19	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
20	Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers. Movement Disorders, 2022, 37, 669-683.	2.2	30
21	Dataâ€driven staging of genetic frontotemporal dementia using multiâ€modal <scp>MRI</scp>. Human Brain Mapping, 2022, 43, 1821-1835.	1.9	7
22	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. Nature Reviews Neurology, 2022, 18, 158-172.	4.9	205
23	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.4	24
24	Prodynorphin and Proenkephalin in Cerebrospinal Fluid of Sporadic Creutzfeldtâ€"Jakob Disease. International Journal of Molecular Sciences, 2022, 23, 2051.	1.8	5
25	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
26	Serum neurofilament light-chain levels in children with monophasic myelin oligodendrocyte glycoprotein-associated disease, multiple sclerosis, and other acquired demyelinating syndrome. Multiple Sclerosis Journal, 2022, 28, 1553-1561.	1.4	20
27	Anomia is present pre-symptomatically in frontotemporal dementia due to MAPT mutations. Journal of Neurology, 2022, 269, 4322-4332.	1.8	1
28	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	1.7	1
29	Frontotemporal Lobar Degeneration Case with an N-Terminal TUBA4A Mutation Exhibits Reduced TUBA4A Levels in the Brain and TDP-43 Pathology. Biomolecules, 2022, 12, 440.	1.8	5
30	Serum <scp>Betaâ€Synuclein</scp> Is Higher in Down Syndrome and Precedes Rise of <scp>pTau181</scp>. Annals of Neurology, 2022, 92, 6-10.	2.8	9
31	Development of a sensitive trial-ready poly(GP) CSF biomarker assay forC9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 761-771.	0.9	12
32	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.4	26
33	Quantitative analysis of regional distribution of tau pathology with 11C-PBB3-PET in a clinical setting. PLoS ONE, 2022, 17, e0266906.	1.1	7
34	Comparative analysis of machine learning algorithms for multi-syndrome classification of neurodegenerative syndromes. Alzheimer's Research and Therapy, 2022, 14, 62.	3.0	9
35	Longitudinal Cognitive Changes in Genetic Frontotemporal Dementia Within the GENFI Cohort. Neurology, 2022, 99, .	1.5	5
36	Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data. Neurobiology of Aging, 2022, 117, 212-221.	1.5	4

#	Article	IF	Citations
37	Increased NF-L levels in the TDP-43G298S ALS mouse model resemble NF-L levels in ALS patients. Acta Neuropathologica, 2022, 144, 161-164.	3.9	1
38	Serum GFAP differentiates Alzheimerâ€™s disease from frontotemporal dementia and predicts MCI-to-dementia conversion. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 659-667.	0.9	21
39	Serum glial fibrillary acidic protein indicates memory impairment in patients with chronic heart failure. ESC Heart Failure, 2022, 9, 2626-2634.	1.4	11
40	Factors associated with mortality in early stages of parkinsonism. Npj Parkinson's Disease, 2022, 8, .	2.5	4
41	Specific Cerebrospinal Fluid SerpinA1 Isoform Pattern in Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2022, 23, 6922.	1.8	2
42	Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntingtonâ€™s and Parkinsonâ€™s disease. Journal of Neurology, 2022, 269, 5136-5143.	1.8	6
43	Cerebrospinal Fluid Levels of Prodynorphinâ€Derived Peptides are Decreased in Huntington's Disease. Movement Disorders, 2021, 36, 492-497.	2.2	12
44	Fluid biomarkers in frontotemporal dementia: past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 204-215.	0.9	62
45	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
46	Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes. Alzheimer's and Dementia, 2021, 17, 969-983.	0.4	31
47	Necrosomeâ€positive granulovacuolar degeneration is associated with TDPâ€43 pathological lesions in the hippocampus of ALS/FTLD cases. Neuropathology and Applied Neurobiology, 2021, 47, 328-345.	1.8	15
48	Guillainâ€“BarrÃ© syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. Journal of Neurology, 2021, 268, 1133-1170.	1.8	286
49	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	1.2	11
50	Differential effect of ethanol intoxication on peripheral markers of cerebral injury in murine blunt traumatic brain injury. Burns and Trauma, 2021, 9, tkab027.	2.3	4
51	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	2.8	42
52	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.1	14
53	Comparison of MRI-based and PET-based image pre-processing for quantification of 11C-PBB3 uptake in human brain. Zeitschrift Fur Medizinische Physik, 2021, 31, 37-47.	0.6	1
54	Quantifying progression in primary progressive aphasia with structural neuroimaging. Alzheimer's and Dementia, 2021, 17, 1595-1609.	0.4	22

#	Article	IF	Citations
55	MRI data-driven algorithm for the diagnosis of behavioural variant frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 608-616.	0.9	10
56	Protein Binding Partners of Dysregulated miRNAs in Parkinsonâ€™s Disease Serum. Cells, 2021, 10, 791.	1.8	11
57	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 946-958.	0.4	16
58	Ongoing challenges in unravelling the association between COVID-19 and Guillain-BarrÃ© syndrome. Brain, 2021, 144, e44-e44.	3.7	6
59	Plasma Neurofilament Light for Prediction of Disease Progression in Familial Frontotemporal Lobar Degeneration. Neurology, 2021, 96, e2296-e2312.	1.5	52
60	Resting-State Alterations in Behavioral Variant Frontotemporal Dementia are Related to the Distribution of Monoamine and GABA Neurotransmitter Systems. Biological Psychiatry, 2021, 89, S177.	0.7	2
61	Different Inflammatory Signatures in Alzheimerâ€™s Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	1.2	18
62	Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. European Journal of Paediatric Neurology, 2021, 32, 93-97.	0.7	7
63	Characterizing the Clinical Features and Atrophy Patterns of MAPT -Related Frontotemporal Dementia With Disease Progression Modeling. Neurology, 2021, 97, e941-e952.	1.5	29
64	ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimerâ€™s disease. Nature Aging, 2021, 1, 521-534.	5.3	64
65	Neurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Frontiers in Neuroscience, 2021, 15, 679199.	1.4	66
66	Motor speech disorders in the nonfluent, semantic and logopenic variants of primary progressive aphasia. Cortex, 2021, 140, 66-79.	1.1	10
67	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	3.0	12
68	Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy. Orphanet Journal of Rare Diseases, 2021, 16, 330.	1.2	12
69	Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Translational Neurodegeneration, 2021, 10, 31.	3.6	18
70	Dissemination in time and space in presymptomatic granulin mutation carriers: a GENFI spatial chronnectome study. Neurobiology of Aging, 2021, 108, 155-167.	1.5	3
71	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. Journal of Psychiatric Research, 2021, 144, 54-58.	1.5	34
72	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	1.4	28

#	Article	IF	Citations
73	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
74	Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 349-356.	0.9	31
75	Clinico-genetic findings in 509 frontotemporal dementia patients. Molecular Psychiatry, 2021, 26, 5824-5832.	4.1	23
76	Differences in Sex Distribution Between Genetic and Sporadic Frontotemporal Dementia. Journal of Alzheimer's Disease, 2021, 84, 1153-1161.	1.2	11
77	VaricellaÂzoster virus-induced neurological disease after COVID-19 vaccination: a retrospective monocentric study. Journal of Neurology, 2021, , 1.	1.8	10
78	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	4.4	9
79	Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosis. Expert Review of Proteomics, 2021, 18, 977-994.	1.3	5
80	Predicting disease progression in behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12262.	1.2	4
81	Neurofilament light chain in serum of adolescent and adult SMA patients under treatment with nusinersen. Journal of Neurology, 2020, 267, 36-44.	1.8	47
82	CSF and blood Kallikrein-8: a promising early biomarker for Alzheimerâ€™s disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 40-48.	0.9	16
83	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis. Acta Neuropathologica, 2020, 139, 119-134.	3.9	73
84	Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry,the, 2020, 7, 93-108.	3.7	252
85	CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimer's Research and Therapy, 2020, 12, 2.	3.0	86
86	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	4.9	175
87	Special Issue CCA for the proceedings of the 2nd symposium of the Society of CSF analysis and Clinical Neurochemistry. Clinica Chimica Acta, 2020, 502, 199-200.	0.5	0
88	Disentangling brain functional network remodeling in corticobasal syndrome â€“ A multimodal MRI study. NeuroImage: Clinical, 2020, 25, 102112.	1.4	10
89	Serum neurofilament light chain (NFL) remains unchanged during electroconvulsive therapy. World Journal of Biological Psychiatry, 2020, 21, 148-154.	1.3	18
90	Tick-Borne Encephalitis: A Differential Pattern of Intrathecal Humoral Immune Response and Inflammatory Cell Composition Compared with Other Viral CNS Infections. Cells, 2020, 9, 2169.	1.8	3

#	Article	IF	Citations
91	Serum neurofilament light chain. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.1	25
92	Rapid, convenient and efficient kit-independent detection of SARS-CoV-2 RNA. Journal of Virological Methods, 2020, 286, 113965.	1.0	10
93	Virtually in this together â€“ how web-conferencing systems enabled a new virtual togetherness during the COVID-19 crisis. European Journal of Information Systems, 2020, 29, 563-584.	5.5	157
94	A Score Based on NfL and Glial Markers May Differentiate Between Relapsingâ€“Remitting and Progressive MS Course. Frontiers in Neurology, 2020, 11, 608.	1.1	25
95	Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis. Scientific Reports, 2020, 10, 8776.	1.6	4
96	Network Localization of Alien Limb in Patients with Corticobasal Syndrome. Annals of Neurology, 2020, 88, 1118-1131.	2.8	11
97	Cerebrospinal Fluid Biomarkers in Relation to MRZ Reaction Status in Primary Progressive Multiple Sclerosis. Cells, 2020, 9, 2543.	1.8	8
98	Early symptoms in symptomatic and preclinical genetic frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 975-984.	0.9	25
99	Abnormal pain perception is associated with thalamo-cortico-striatal atrophy in C9orf72 expansion carriers in the GENFI cohort. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1325-1328.	0.9	12
100	Millerâ€Fisher syndrome after COVIDâ€19: neurochemical markers as an early sign of nervous system involvement. European Journal of Neurology, 2020, 27, 2378-2380.	1.7	51
101	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	0.9	36
102	Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies. Biomedicines, 2020, 8, 312.	1.4	16
103	Dipeptide repeat protein and TDP-43 pathology along the hypothalamicâ€“pituitary axis in C9orf72 and non-C9orf72 ALS and FTLD-TDP cases. Acta Neuropathologica, 2020, 140, 777-781.	3.9	8
104	Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19. Journal of the Neurological Sciences, 2020, 418, 117106.	0.3	17
105	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	1.5	20
106	Markers of vitamin B12 status in relation to cerebrospinal fluid biomarkers and cognitive performance. Proceedings of the Nutrition Society, 2020, 79, .	0.4	1
107	Stress cardiomyopathy associated with the first manifestation of multiple sclerosis: a case report. BMC Neurology, 2020, 20, 227.	0.8	6
108	A multi-center study of neurofilament assay reliability and inter-laboratory variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 452-458.	1.1	15

#	Article	IF	Citations
109	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. Molecular Neurodegeneration, 2020, 15, 36.	4.4	46
110	Different CSF protein profiles in amyotrophic lateral sclerosis and frontotemporal dementia with C9orf72 hexanucleotide repeat expansion. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 503-511.	0.9	33
111	Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimerâ€™s Disease. Journal of Proteome Research, 2020, 19, 1310-1318.	1.8	43
112	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
113	CSF SerpinA1 in Creutzfeldtâ€“Jakob disease and frontotemporal lobar degeneration. Annals of Clinical and Translational Neurology, 2020, 7, 191-199.	1.7	16
114	S-ketamine induces acute changes in the proteome of the mouse amygdala. Journal of Proteomics, 2020, 216, 103679.	1.2	6
115	CSF Ubiquitin Levels Are Higher in Alzheimerâ€™s Disease than in Frontotemporal Dementia and Reflect the Molecular Subtype in Prion Disease. Biomolecules, 2020, 10, 497.	1.8	8
116	Distinct molecular patterns of TDP-43 pathology in Alzheimerâ€™s disease: relationship with clinical phenotypes. Acta Neuropathologica Communications, 2020, 8, 61.	2.4	58
117	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 612-621.	0.9	55
118	S1 guidelines â€œlumbar puncture and cerebrospinal fluid analysisâ€•(abridged and translated version). Neurological Research and Practice, 2020, 2, 8.	1.0	23
119	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic C9orf72 Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	2.8	19
120	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26
121	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. Translational Psychiatry, 2020, 10, 144.	2.4	20
122	Regional tau deposition in probable Alzheimerâ€™s disease using C-11-PBB3-PET: a voxel-wise statistical analysis. Nuklearmedizin - NuclearMedicine, 2020, 59, .	0.3	0
123	AADVAC1, AN ACTIVE IMMUNOTHERAPY FOR ALZHEIMERâ€™S DISEASE AND NON ALZHEIMER TAUOPATHIES: AN OVERVIEW OF PRECLINICAL AND CLINICAL DEVELOPMENT. journal of prevention of Alzheimer's disease, The, 2019, 6, 1-7.	1.5	44
124	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2019, 7, 114.	2.4	11
125	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. International Journal of Molecular Sciences, 2019, 20, 4674.	1.8	26
126	Association of cerebrospinal fluid kappa free light chains with the intrathecal polyspecific antiviral immune response in multiple sclerosis. Clinica Chimica Acta, 2019, 498, 148-153.	0.5	7

#	Article	IF	Citations
127	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	4.9	128
128	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	3.7	1
129	Neurofilaments and tau in CSF in an infant with SMA type 1 treated with nusinersen. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1068.2-1069.	0.9	44
130	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimerâ€™s Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
131	FDG-PET underscores the key role of the thalamus in frontotemporal lobar degeneration caused by C9ORF72 mutations. Translational Psychiatry, 2019, 9, 54.	2.4	28
132	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
133	ElecsysÂ® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
134	Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641984605.	1.5	41
135	Education modulates brain maintenance in presymptomatic frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1124-1130.	0.9	23
136	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	3.0	325
137	CSF Free Light Chains as a Marker of Intrathecal Immunoglobulin Synthesis in Multiple Sclerosis: A Blood-CSF Barrier Related Evaluation in a Large Cohort. Frontiers in Immunology, 2019, 10, 641.	2.2	34
138	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology, 2019, 92, e1479-e1486.	1.5	100
139	Unraveling corticobasal syndrome and alien limb syndrome with structural brain imaging. Cortex, 2019, 117, 33-40.	1.1	17
140	Glial Activation Markers in CSF and Serum From Patients With Primary Progressive Multiple Sclerosis: Potential of Serum GFAP as Disease Severity Marker?. Frontiers in Neurology, 2019, 10, 280.	1.1	87
141	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. Journal of Psychiatric Research, 2019, 113, 137-140.	1.5	81
142	A ferroptosisâ€“based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Scientific Reports, 2019, 9, 2918.	1.6	91
143	Different aspects of Alzheimerâ€™s disease-related amyloid Î²-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. Acta Neuropathologica Communications, 2019, 7, 178.	2.4	29
144	Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. Frontiers in Neurology, 2019, 10, 1179.	1.1	18

#	Article	IF	Citations
145	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
146	Neurochemical biomarkers in amyotrophic lateral sclerosis. Current Opinion in Neurology, 2019, 32, 747-757.	1.8	24
147	A Review on MS-Based Blood Biomarkers for Alzheimerâ€™s Disease. Neurology and Therapy, 2019, 8, 113-127.	1.4	35
148	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 4-10.	0.9	96
149	Biomarkers for diseases with TDP-43 pathology. Molecular and Cellular Neurosciences, 2019, 97, 43-59.	1.0	38
150	â€œMicrochip Electrophoresis,â€•with Respect to â€œProfiling of AÎ² Peptides in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Diseaseâ€• Methods in Molecular Biology, 2019, 1855, 327-340.	0.4	4
151	Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 157-164.	0.9	174
152	Moral judgment in patients with behavioral variant of frontotemporal dementia and amyotrophic lateral sclerosis: no impairment of the moral position, but rather its execution. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 12-18.	1.1	7
153	On Razor's edge: Managing analgosedation during severe anti-NMDA receptor encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e522.	3.1	1
154	The applause sign in frontotemporal lobar degeneration and related conditions. Journal of Neurology, 2019, 266, 330-338.	1.8	15
155	Story of the ALS-FTD continuum retold: rather two distinct entities. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 586-589.	0.9	26
156	Analysis of CACNA1A CAG repeat lengths in patients with familialÂALS. Neurobiology of Aging, 2019, 74, 235.e5-235.e8.	1.5	6
157	Comprehensive micro<scp>RNA</scp> expression profiling in cerebrospinal fluid distinguishes between neurological disease classes. Neuropathology and Applied Neurobiology, 2019, 45, 318-323.	1.8	1
158	The cryo-electron microscopy structure of huntingtin. Nature, 2018, 555, 117-120.	13.7	125
159	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	3.7	167
160	Relationship between cerebrospinal fluid concentrations of orexin A/hypocretin-1 and body composition in humans. Peptides, 2018, 102, 26-30.	1.2	5
161	Intrathecal immunoglobulin M production: A promising highâ€risk marker in clinically isolated syndrome patients. Annals of Neurology, 2018, 83, 1032-1036.	2.8	23
162	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Neurobiology of Aging, 2018, 67, 21-22.	1.5	6

#	Article	IF	Citations
163	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	0.9	80
164	The molecular tweezer CLR01 inhibits Ebola and Zika virus infection. Antiviral Research, 2018, 152, 26-35.	1.9	31
165	Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?Â© Caroline Moreau et al. 2018; Published by Mary Ann Liebert, Inc. This Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.. Antioxidants and Redox Signaling, 2018, 29, 742-748.	2.5	86
166	Comment: Tau CSF proteins for diagnosis but tau PET imaging for AD diagnosis and staging. Neurology, 2018, 90, 216-216.	1.5	1
167	Online Preconcentration in Capillaries by Multiple Large-Volume Sample Stacking: An Alternative to Immunoassays for Quantification of Amyloid Beta Peptides Biomarkers in Cerebrospinal Fluid. Analytical Chemistry, 2018, 90, 2555-2563.	3.2	25
168	CHCHD10 mutations p.R15L and p.G66V cause motoneuron disease by haploinsufficiency. Human Molecular Genetics, 2018, 27, 706-715.	1.4	30
169	Alpha-synuclein is present in dental calculus but not altered in Parkinsonâ€™s disease patients in comparison to controls. Journal of Neurology, 2018, 265, 1334-1337.	1.8	1
170	A language-based sum score for the course and therapeutic intervention in primary progressive aphasia. Alzheimer's Research and Therapy, 2018, 10, 41.	3.0	8
171	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	3.0	40
172	Capillary cerebral amyloid angiopathy in Alzheimerâ€™s disease: association with allocortical/hippocampal microinfarcts and cognitive decline. Acta Neuropathologica, 2018, 135, 681-694.	3.9	70
173	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	1.3	215
174	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.5	148
175	Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 239-247.	0.9	89
176	TCT-4 Reduction of stroke with use of the double-filter cerebral embolic protection device in patients undergoing transfemoral aortic valve replacement with self-expandable, mechanically implantable and balloon-expandable aortic valves. Journal of the American College of Cardiology, 2018, 72, B2.	1.2	2
177	Serum GFAP as a biomarker for disease severity in multiple sclerosis. Scientific Reports, 2018, 8, 14798.	1.6	164
178	Glycoprotein NMB: a novel Alzheimerâ€™s disease associated marker expressed in a subset of activated microglia. Acta Neuropathologica Communications, 2018, 6, 108.	2.4	107
179	Serum neurofilament light chain in behavioral variant frontotemporal dementia. Neurology, 2018, 91, e1390-e1401.	1.5	85
180	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of AÎ² species. NeuroImage: Clinical, 2018, 20, 603-610.	1.4	11

#	Article	IF	Citations
181	Specific serum and CSF microRNA profiles distinguish sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and cognitively healthy controls. PLoS ONE, 2018, 13, e0197329.	1.1	68
182	Neurofilaments as biomarkers in neurological disorders. Nature Reviews Neurology, 2018, 14, 577-589.	4.9	1,177
183	A Modified Reading the Mind in the Eyes Test Predicts Behavioral Variant Frontotemporal Dementia Better Than Executive Function Tests. Frontiers in Aging Neuroscience, 2018, 10, 11.	1.7	34
184	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients â€“ An Atlas-Based Volumetric MRI Study. Frontiers in Aging Neuroscience, 2018, 10, 45.	1.7	40
185	Longitudinal Diffusion Tensor Imaging Resembles Patterns of Pathology Progression in Behavioral Variant Frontotemporal Dementia (bvFTD). Frontiers in Aging Neuroscience, 2018, 10, 47.	1.7	13
186	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS. Cellular and Molecular Life Sciences, 2018, 75, 4301-4319.	2.4	34
187	Micro-droplet arrays for micro-compartmentalization using an air/water interface. Lab on A Chip, 2018, 18, 2797-2805.	3.1	18
188	Semen inhibits Zika virus infection of cells and tissues from the anogenital region. Nature Communications, 2018, 9, 2207.	5.8	41
189	Comparison of Internal Standard Approaches for SRM Analysis of Alpha-Synuclein in Cerebrospinal Fluid. Journal of Proteome Research, 2018, 17, 516-523.	1.8	23
190	D04â€...Blood-CSF barrier function and CSF flow influence CSF biomarkers in huntingtonâ€™s disease. , 2018, , .		0
191	Predicting primary progressive aphasias with support vector machine approaches in structural MRI data. NeuroImage: Clinical, 2017, 14, 334-343.	1.4	42
192	Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology, 2017, 88, 961-969.	1.5	73
193	Predicting behavioral variant frontotemporal dementia with pattern classification in multi-center structural MRI data. NeuroImage: Clinical, 2017, 14, 656-662.	1.4	64
194	Polyâ€<scp>GP</scp> in cerebrospinal fluid links C9orf72â€associated dipeptide repeat expression to the asymptomatic phase of <scp>ALS</scp>/<scp>FTD</scp>. EMBO Molecular Medicine, 2017, 9, 859-868.	3.3	90
195	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. Expert Review of Proteomics, 2017, 14, 499-514.	1.3	26
196	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
197	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
198	Neurofilaments in blood. Neurology, 2017, 89, 2126-2127.	1.5	0

#	Article	IF	Citations
199	Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement Significantly Reduces Death and Stroke Compared With Unprotected Procedures. JACC: Cardiovascular Interventions, 2017, 10, 2297-2303.	1.1	136
200	Proteomic studies in the discovery of cerebrospinal fluid biomarkers for amyotrophic lateral sclerosis. Expert Review of Proteomics, 2017, 14, 769-777.	1.3	27
201	[P4â€“189]: SYMPTOM ONSET IN GENETIC FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P1337.	0.4	2
202	Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression. Alzheimer's Research and Therapy, 2017, 9, 17.	3.0	30
203	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.1	63
204	Disease-Specific Regions Outperform Whole-Brain Approaches in Identifying Progressive Supranuclear Palsy: A Multicentric MRI Study. Frontiers in Neuroscience, 2017, 11, 100.	1.4	10
205	Development and Validation of an Ultrasensitive Procalcitonin Sandwich Immunoassay. High-Throughput, 2017, 6, 18.	4.4	8
206	Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2015-311387.	0.9	207
207	TDPâ€43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons. EMBO Journal, 2016, 35, 2350-2370.	3.5	76
208	Modified serpinA1 as risk marker for Parkinsonâ€™s disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
209	Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Scientific Reports, 2016, 6, 38737.	1.6	81
210	Detection of intrathecal immunoglobulin G synthesis by capillary isoelectric focusing immunoassay in oligoclonal band negative multiple sclerosis. Journal of Neurology, 2016, 263, 954-960.	1.8	13
211	Improved concordance between [11C]PIB PET and CSF AÎ²42 using AÎ²42/AÎ²40: findings from a multicentre European memory clinic population. Neurobiology of Aging, 2016, 39, S18.	1.5	1
212	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.1	84
213	Amyloidâ€beta oligomerization is associated with the generation of a typical peptide fragment fingerprint. Alzheimer's and Dementia, 2016, 12, 996-1013.	0.4	17
214	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-Î² in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	3.7	107
215	Atrophy and structural covariance of the cholinergic basal forebrain in primary progressive aphasia. Cortex, 2016, 83, 124-135.	1.1	21
216	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimerâ€²s and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. Molecular and Cellular Proteomics, 2016, 15, 3126-3138.	2.5	92

#	Article	IF	Citations
217	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a Germanâ€“Austrian retrospective multicenter study in patients with a clinically isolated syndrome. Journal of Neurology, 2016, 263, 2499-2504.	1.8	46
218	Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Annals of Neurology, 2016, 79, 152-158.	2.8	188
219	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. Movement Disorders, 2016, 31, 848-860.	2.2	52
220	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. Journal of Neurochemistry, 2016, 138, 184-192.	2.1	26
221	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2016, 3, 623-636.	1.7	207
222	Validation of a multiplexing technique to determine the intrathecal, polyspecific antiviral immune response in multiple sclerosis. Expert Review of Molecular Diagnostics, 2016, 16, 1353-1356.	1.5	2
223	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1Î². BMC Neurology, 2016, 16, 185.	0.8	64
224	Aggregated Î±-Synuclein Increases SOD1 Oligomerization in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2016, 186, 2152-2161.	1.9	17
225	Progranulin as a candidate biomarker for therapeutic trial in patients with ALS and FTLD. Journal of Neural Transmission, 2016, 123, 289-296.	1.4	26
226	Water-soluble allyl sulfones for dual site-specific labelling of proteins and cyclic peptides. Chemical Science, 2016, 7, 3234-3239.	3.7	66
227	NEK1mutations in familial amyotrophic lateral sclerosis. Brain, 2016, 139, e28-e28.	3.7	105
228	Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia. PLoS ONE, 2016, 11, e0164953.	1.1	21
229	An integrated microfluidic chip for immunocapture, preconcentration and separation of Î²-amyloid peptides. Biomicrofluidics, 2015, 9, 054117.	1.2	35
230	Detection and Differentiation of Threonine- and Tyrosine-Monophosphorylated Forms of ERK1/2 by Capillary Isoelectric Focusing-Immunoassay. Scientific Reports, 2015, 5, 12767.	1.6	5
231	Role of glial 14-3-3 gamma protein in autoimmune demyelination. Journal of Neuroinflammation, 2015, 12, 187.	3.1	12
232	Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?. International Journal of Molecular Sciences, 2015, 16, 17565-17588.	1.8	20
233	Laboratory Diagnosis of Subarachnoid Haemorrhage. , 2015, , 387-394.		0
234	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2015, 1854, 757-768.	1.1	21

#	Article	IF	Citations
235	Capillary isoelectric focusing immunoassay as a new nanoscale approach for the detection of oligoclonal bands. Electrophoresis, 2015, 36, 355-362.	1.3	11
236	Distribution of dipeptide repeat proteins in cellular models and C9orf72 mutation cases suggests link to transcriptional silencing. Acta Neuropathologica, 2015, 130, 537-555.	3.9	157
237	Serum microRNAs in sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2015, 36, 2660.e15-2660.e20.	1.5	64
238	Quantifying amyloid fibrils in protein mixtures via infrared attenuated-total-reflection spectroscopy. Analytical and Bioanalytical Chemistry, 2015, 407, 4015-4021.	1.9	20
239	The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. Alzheimer's and Dementia, 2015, 11, 1407-1416.	0.4	152
240	Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neuroscience, 2015, 18, 631-636.	7.1	652
241	Mutual exacerbation of peroxisome proliferatorâ€activated receptor Î³ coactivator 1Î± deregulation and Î±â€synuclein oligomerization. Annals of Neurology, 2015, 77, 15-32.	2.8	112
242	Cerebrospinal Fluid Immunoglobulin Kappa Light Chain in Clinically Isolated Syndrome and Multiple Sclerosis. PLoS ONE, 2014, 9, e88680.	1.1	75
243	Intact Protein Analysis of Ubiquitin in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Differences in Alzheimerâ€™s Disease and Frontotemporal Lobar Degeneration. Journal of Proteome Research, 2014, 13, 4518-4525.	1.8	41
244	Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 351-356.	1.1	131
245	Serum microRNAs in patients with genetic amyotrophic lateral sclerosis and pre-manifest mutation carriers. Brain, 2014, 137, 2938-2950.	3.7	91
246	Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by paraffin-embedded tissue (PET) blot. Acta Neuropathologica Communications, 2014, 2, 130.	2.4	8
247	Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 344-350.	1.1	62
248	B32 Alterations in Mitochondrial Proteome of Brain and Skeletal Muscle in Two Transgenic HD Mouse Models do not Reflect Mitochondrial Respiratory Activity. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A20-A20.	0.9	0
249	Protease-resistant SOD1 aggregates in amyotrophic lateral sclerosis demonstrated by Paraffin Embedded Tissue (PET) blot. Acta Neuropathologica Communications, 2014, 2, 130.	2.4	5
250	Onâ€line capillary electrophoresis derivatization method for high sensitivity analysis of ubiquitin in filtered cerebrospinal fluid. Electrophoresis, 2013, 34, 2733-2739.	1.3	6
251	Influence of the blood-CSF-barrier function on S100B in neurodegenerative diseases. Acta Neurologica Scandinavica, 2013, 128, 249-256.	1.0	9
252	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurology, The, 2013, 12, 233-243.	4.9	177

#	Article	IF	Citations
253	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.4	344
254	Acute onset of adult Alexander disease. Journal of the Neurological Sciences, 2013, 331, 152-154.	0.3	17
255	Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsy. Sleep Medicine, 2013, 14, 692-694.	0.8	13
256	Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2073-2086.	1.4	37
257	Increased Levels of Antigen-Bound Î²-Amyloid Autoantibodies in Serum and Cerebrospinal Fluid of Alzheimerâ€™s Disease Patients. PLoS ONE, 2013, 8, e68996.	1.1	45
258	Chitinase enzyme activity in CSF is a powerful biomarker of Alzheimer disease. Neurology, 2012, 78, 569-577.	1.5	106
259	Development of a magnetic immunosorbent for on-chip preconcentration of amyloid Î² isoforms: Representatives of Alzheimerâ€™s disease biomarkers. Biomicrofluidics, 2012, 6, 024126.	1.2	29
260	Recent biomarker approaches in the diagnosis of frontotemporal lobar degeneration/Neurochemische AnsÃtze in der Diagnose der Frontotemporalen LobÃrdegeneration. Laboratoriums Medizin, 2012, 36, .	0.1	1
261	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 1-10.	2.3	81
262	Genetic variants in PSEN2 and correlation to CSF Î²-amyloid42 levels in AD. Neurobiology of Aging, 2012, 33, 201.e9-201.e18.	1.5	6
263	Microchip Electrophoresis, with Respect to â€œProfiling of AÎ² Peptides in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Diseaseâ€• Methods in Molecular Biology, 2012, 869, 173-184.	0.4	6
264	Mass spectrometry imaging (MSI) of metals in mouse spinal cord by laser ablation ICP-MS. Metallomics, 2012, 4, 284.	1.0	28
265	CSF Concentrations of cAMP and cGMP Are Lower in Patients with Creutzfeldt-Jakob Disease but Not Parkinson's Disease and Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e32664.	1.1	21
266	A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e37885.	1.1	125
267	Plasma Amyloidâ€‹<scp>Beta</scp>Peptides in Acute Cerebral Ischemia: A Pilot Study. Journal of Clinical Laboratory Analysis, 2012, 26, 238-245.	0.9	3
268	iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. Experimental Neurology, 2012, 234, 499-505.	2.0	57
269	Differential Sialylation of Serpin A1 in the Early Diagnosis of Parkinsonâ€™s Disease Dementia. PLoS ONE, 2012, 7, e48783.	1.1	37
270	Analysis of Amyloid-Î² Peptides in Cerebrospinal Fluid Samples by Capillary Electrophoresis Coupled with LIF Detection. Analytical Chemistry, 2011, 83, 1696-1703.	3.2	31

#	Article	IF	Citations
271	1180 PROTEOMICS IN CEREBROSPINAL FLUID IN PATIENTS WITH HEPATITIS C VIRUS INFECTION AND NEUROPSYCHIATRIC SYMPTOMS. Journal of Hepatology, 2011, 54, S466.	1.8	1
272	14-3-3 proteins in neurodegeneration. Seminars in Cell and Developmental Biology, 2011, 22, 696-704.	2.3	85
273	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2011, 7, 386.	0.4	354
274	Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	1.1	12
275	CSF Amyloid-Î² Peptides in Neuropathologically Diagnosed Dementia with Lewy Bodies and Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 383-391.	1.2	26
276	Soluble Beta-Amyloid Precursor Protein Is Related to Disease Progression in Amyotrophic Lateral Sclerosis. PLoS ONE, 2011, 6, e23600.	1.1	36
277	Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. Journal of Neurology, 2011, 258, 1034-1041.	1.8	67
278	Different CSF Î²-amyloid processing in Alzheimerâ€™s and Creutzfeldtâ€“Jakob disease. Journal of Neural Transmission, 2011, 118, 691-697.	1.4	15
279	Revised McDonald criteria: The persisting importance of cerebrospinal fluid analysis. Annals of Neurology, 2011, 70, 520-520.	2.8	53
280	Cerebrospinal Fluid Tau, p-Tau 181 and Amyloid-Î²_{38/40/42} in Frontotemporal Dementias and Primary Progressive Aphasias. Dementia and Geriatric Cognitive Disorders, 2011, 31, 37-44.	0.7	46
281	The Use of S100B and Tau Protein Concentrations in the Cerebrospinal Fluid for the Differential Diagnosis of Bacterial Meningitis: A Retrospective Analysis. European Neurology, 2011, 66, 128-132.	0.6	13
282	The Role of Clusterin, Complement Receptor 1, and Phosphatidylinositol Binding Clathrin Assembly Protein in Alzheimer Disease Risk and Cerebrospinal Fluid Biomarker Levels. Archives of General Psychiatry, 2011, 68, 207.	13.8	83
283	ERK2 is Increased in Cerebrospinal Fluid of Creutzfeldt-Jakob Disease Patients. Journal of Alzheimer's Disease, 2010, 22, 119-128.	1.2	9
284	A12â€…Mitochondrial proteome analysis of R6/2 mouse brains. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, A4.2-A4.	0.9	0
285	Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure. Journal of Neural Transmission, 2010, 117, 353-367.	1.4	10
286	Differential pattern of brainâ€specific CSF proteins tau and amyloidâ€beta in Parkinsonian syndromes. Movement Disorders, 2010, 25, 1284-1288.	2.2	44
287	Ubiquitin as potential cerebrospinal fluid marker of Creutzfeldtâ€“Jakob disease. Proteomics, 2010, 10, 81-89.	1.3	39
288	14-3-3 adaptor proteins recruit AID to 5â€²-AGCT-3â€²â€“rich switch regions for class switch recombination. Nature Structural and Molecular Biology, 2010, 17, 1124-1135.	3.6	122

#	Article	IF	Citations
289	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. International Journal of Alzheimer's Disease, 2010, 2010, 1-12.	1.1	16
290	Combined Analysis of CSF Tau, AÎ²42, AÎ²1â€“42% and AÎ²1â€“40ox% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia. International Journal of Alzheimer's Disease, 2010, 2010, 1-7.	1.1	17
291	2D DIGE of the cerebrospinal fluid proteome in neurological diseases. Expert Review of Proteomics, 2010, 7, 29-38.	1.3	23
292	Dementia Diagnostics 2.0â€"Transfer from Research Studies into Routine Clinical Practice. Clinical Chemistry, 2010, 56, 152-153.	1.5	1
293	Microchip Electrophoresis Profiling of AÎ² Peptides in the Cerebrospinal Fluid of Patients with Alzheimerâ€™s Disease. Analytical Chemistry, 2010, 82, 7611-7617.	3.2	39
294	S100B in the cerebrospinal fluidâ€"A marker for glial damage in the rabbit model of pneumococcal meningitis. Neuroscience Letters, 2010, 475, 104-107.	1.0	11
295	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental Neurology, 2010, 223, 432-438.	2.0	10
296	Neuroprotective Function of Cellular Prion Protein in a Mouse Model of Amyotrophic Lateral Sclerosis. American Journal of Pathology, 2010, 176, 1409-1420.	1.9	37
297	A Proteomic Approach for the Diagnosis of Bacterial Meningitis. PLoS ONE, 2010, 5, e10079.	1.1	17
298	The Chemokine CXCL13 Is a Prognostic Marker in Clinically Isolated Syndrome (CIS). PLoS ONE, 2010, 5, e11986.	1.1	122
299	Trabalho de consenso de forÃ§a-tarefa da WFSBP sobre marcadores biolÃ³gicos das demÃªncias: contribuiÃ§Ã£o da anÃ¡lise do LCR e do sangue para o diagnÃ³stico precoce e diferencial das demÃªncias. Revista De Psiquiatria Clinica, 2009, 36, 1-16.	0.6	1
300	IgG Antibodies against Measles, Rubella, and Varicella Zoster Virus Predict Conversion to Multiple Sclerosis in Clinically Isolated Syndrome. PLoS ONE, 2009, 4, e7638.	1.1	106
301	Moyamoya disease precipitating Sydenham's chorea in a 19â€yearâ€old Caucasian woman. Movement Disorders, 2009, 24, 1401-1403.	2.2	1
302	Combined CSF tau, p-tau181 and amyloid-Î² 38/40/42 for diagnosing Alzheimerâ€™s disease. Journal of Neural Transmission, 2009, 116, 203-212.	1.4	124
303	Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Journal of Neural Transmission, 2009, 116, 1169-1178.	1.4	26
304	Free caspase activity in CSF of patients with dementia. Journal of Neurology, 2009, 256, 1561-1562.	1.8	4
305	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology, 2009, 16, 297-309.	1.7	170
306	Cerebrospinal fluid and serum NT-proBNP concentrations in children with epilepsy. Epilepsy Research, 2009, 86, 131-137.	0.8	3

#	Article	IF	Citations
307	Cognitive Impairment and Dementia in Elderly People Living in Rural Benin, West Africa. Dementia and Geriatric Cognitive Disorders, 2009, 27, 34-41.	0.7	61
308	Glial Fibrillary Acidic Protein and Protein S-100B: Different Concentration Pattern of Glial Proteins in Cerebrospinal Fluid of Patients with Alzheimer's Disease and Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2009, 17, 541-551.	1.2	74
309	Neurochemical Approaches in the Laboratory Diagnosis of Parkinson and Parkinson Dementia Syndromes: A Review. CNS Neuroscience and Therapeutics, 2009, 15, 157-182.	1.9	33
310	Hypocretin Measurement in an Icelandic Foal with Narcolepsy. Journal of Veterinary Internal Medicine, 2009, 23, 1299-1302.	0.6	12
311	Cerebrospinal fluid analysis for diagnosis of noninflammatory, dementive and psychiatric diseases. Acta Neuropsychiatrica, 2009, 21, 58-61.	1.0	26
312	Proteome Profiling in Murine Models of Multiple Sclerosis: Identification of Stage Specific Markers and Culprits for Tissue Damage. PLoS ONE, 2009, 4, e7624.	1.1	43
313	Neurochemical dementia diagnostics: assays in CSF and blood. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 44-49.	1.8	10
314	Cerebrospinal fluidâ€optimized twoâ€dimensional difference gel electrophoresis (2â€D DIGE) facilitates the differential diagnosis of Creutzfeldtâ€“Jakob disease. Proteomics, 2008, 8, 4357-4366.	1.3	66
315	CSF amyloidâ€Î² 1â€38 and 1â€42 in FTD and AD: Biomarker performance critically depends on the detergent accessible fraction. Proteomics - Clinical Applications, 2008, 2, 1548-1556.	0.8	25
316	Simultaneous analysis by capillary electrophoresis of five amyloid peptides as potential biomarkers of Alzheimer's disease. Journal of Chromatography A, 2008, 1214, 157-164.	1.8	39
317	Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ42reduces their differentiation potential. BMC Medicine, 2008, 6, 38.	2.3	13
318	Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis. Neuroscience Letters, 2008, 436, 72-76.	1.0	60
319	Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: A multicenter study. Neurobiology of Aging, 2008, 29, 812-818.	1.5	94
320	Severe sensorimotor neuropathy after intake of highest dosages of vitamin B6. Neuromuscular Disorders, 2008, 18, 156-158.	0.3	56
321	Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases. Methods, 2008, 44, 289-298.	1.9	38
322	Flupirtine as Neuroprotective Add-On Therapy in Autoimmune Optic Neuritis. American Journal of Pathology, 2008, 173, 1496-1507.	1.9	34
323	TDP-43 in Cerebrospinal Fluid of Patients With Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Archives of Neurology, 2008, 65, 1481.	4.9	186
324	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. Expert Review of Molecular Diagnostics, 2008, 8, 479-494.	1.5	77

#	Article	IF	Citations
325	Prion-Erkrankungen. , 2008, , 901-912.		0
326	Serum Heart-Type Fatty Acid-Binding Protein and Cerebrospinal Fluid Tau: Marker Candidates for Dementia with Lewy Bodies. Neurodegenerative Diseases, 2007, 4, 366-375.	0.8	65
327	Proteomic Analysis of the Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. Dementia and Geriatric Cognitive Disorders, 2007, 23, 22-28.	0.7	11
328	Validation of amyloid-Î² peptides in CSF diagnosis of neurodegenerative dementias. Molecular Psychiatry, 2007, 12, 671-680.	4.1	85
329	Bloodâ€based neurochemical diagnosis of vascular dementia: a pilot study. Journal of Neurochemistry, 2007, 103, 467-474.	2.1	55
330	Tauopathies and synucleinopathies: Do cerebrospinal fluid Î²-amyloid peptides reflect disease-specific pathogenesis?. Journal of Neural Transmission, 2007, 114, 919-927.	1.4	33
331	Beta-Amlyoid 1â€“42 and Tau-Protein in Cerebrospinal Fluid of Patients with Parkinsonâ€™s Disease Dementia. Dementia and Geriatric Cognitive Disorders, 2006, 22, 200-208.	0.7	114
332	International quality control survey of neurochemical dementia diagnostics. Neuroscience Letters, 2006, 409, 1-4.	1.0	102
333	Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldtâ€“Jakob disease. Neurobiology of Aging, 2006, 27, 10-15.	1.5	69
334	CSF diagnosis of Alzheimerâ€™s disease and dementia with Lewy bodies. Journal of Neural Transmission, 2006, 113, 1771-1778.	1.4	58
335	CSF amyloid-Î²-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain, 2006, 129, 1177-1187.	3.7	193
336	Selective reduction of amyloid Â42 discriminates Alzheimer's disease from Huntington's disease: indication for distinct pathological events in amyloid Â peptide aggregation. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1201-1203.	0.9	3
337	Total tau protein, phosphorylated tau (181p) protein, Î²-amyloid1â€“42, and Î²-amyloid1â€“40 in cerebrospinal fluid of patients with dementia with Lewy bodies. Clinical Chemistry and Laboratory Medicine, 2006, 44, 192-5.	1.4	65
338	Normal hypocretin-1 (orexin-A) levels in the cerebrospinal fluid of patients with Huntington's disease. Brain Research, 2005, 1063, 201-203.	1.1	46
339	Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimerâ€™s disease. Journal of Neural Transmission, 2005, 112, 933-948.	1.4	59
340	Unchanged Survival Rates of 14-3-3Î³ Knockout Mice after Inoculation with Pathological Prion Protein. Molecular and Cellular Biology, 2005, 25, 1339-1346.	1.1	56
341	Tau, Phospho-Tau, and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis. Journal of Child Neurology, 2005, 20, 822-825.	0.7	37
342	Tau Protein, AÎ²42 and S-100B Protein in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2005, 19, 164-170.	0.7	75

#	Article	IF	Citations
343	Creutzfeldt-Jakob Disease and Homocysteine Levels in Plasma and Cerebrospinal Fluid. Gerontology, 2005, 51, 142-144.	1.4	6
344	Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. World Journal of Biological Psychiatry, 2005, 6, 69-84.	1.3	105
345	Follow-Up Investigations of Tau Protein and S-100B Levels in Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. Dementia and Geriatric Cognitive Disorders, 2005, 19, 376-382.	0.7	13
346	CSF Lactate Dehydrogenase Activity in Patients with Creutzfeldt-Jakob Disease Exceeds That in Other Dementias. Dementia and Geriatric Cognitive Disorders, 2004, 17, 204-206.	0.7	18
347	Lithium Decreases Secretion of AÎ²1â€“42 and C-Truncated Species AÎ²1â€“37/38/39/40 in Chicken Telencephalic Cultures but Specifically Increases Intracellular AÎ²1â€“38. Neurodegenerative Diseases, 2004, 1, 236-241.	0.8	20
348	Efficacy of flupirtine on cognitive function in patients with CJD. Neurology, 2004, 62, 714-718.	1.5	186
349	Value of CSF Î²-amyloid1â€“42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 2004, 9, 705-710.	4.1	280
350	Tau Protein Phosphorylated at Threonine 181 in CSF as a Neurochemical Biomarker in Alzheimer's Disease: Original Data and Review of the Literature. Journal of Molecular Neuroscience, 2004, 23, 115-122.	1.1	97
351	Cerebrospinal fluid amyloidÎ² peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloidÎ² peptides. Electrophoresis, 2004, 25, 2912-2918.	1.3	90
352	Electrophoretic separation of amyloid Î² peptides in plasma. Electrophoresis, 2004, 25, 3336-3343.	1.3	50
353	P3-377 Cerebrospinal fluid investigations in creutzfeldt-jakob disease. Neurobiology of Aging, 2004, 25, S462.	1.5	0
354	Amyloid Î² peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biological Psychiatry, 2004, 55, 524-530.	0.7	86
355	Role of Interleukin-1 in Prion Disease-Associated Astrocyte Activation. American Journal of Pathology, 2004, 165, 671-678.	1.9	85
356	Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neuroscience Letters, 2004, 370, 36-39.	1.0	83
357	Neurochemical diagnosis of Alzheimerâ€™s dementia by CSF AÎ²42, AÎ²42/AÎ²40 ratio and total tau. Neurobiology of Aging, 2004, 25, 273-281.	1.5	267
358	O2-02-05 Surface enhanced laser desorption/ionization time-of-flight mass spectrometry for the differential diagnosis of Creutzfeld-Jakob disease. Neurobiology of Aging, 2004, 25, S34-S35.	1.5	0
359	Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2004, 15, 74-81.	0.7	1
360	Diagnostic problems during late course in Creutzfeldt-Jakob disease. Journal of Neurology, 2003, 250, 629-630.	1.8	17

#	Article	IF	Citations
361	?-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Annals of Neurology, 2003, 54, 263-267.	2.8	82
362	The amyloidâ€•Î² (A Î²) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated A Î² peptide. Rapid Communications in Mass Spectrometry, 2003, 17, 1291-1296.	0.7	106
363	Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldtâ€“Jakob disease from other dementias. Molecular Psychiatry, 2003, 8, 343-347.	4.1	209
364	Different binding pattern of antibodies to prion protein on lymphocytes from patients with sporadic Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 2003, 343, 29-32.	1.0	3
365	Differential diagnosis of neurodegenerative diseases with special emphasis on Creutzfeldt-Jakob disease. Restorative Neurology and Neuroscience, 2003, 21, 191-209.	0.4	18
366	Serum Tau Protein Level as a Marker of Axonal Damage in Acute Ischemic Stroke. European Neurology, 2002, 47, 45-51.	0.6	87
367	Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldtâ€“Jakob disease. Neurology, 2002, 58, 192-197.	1.5	263
368	Specific 14-3-3 isoform detection and immunolocalization in prion diseases. Biochemical Society Transactions, 2002, 30, 387-391.	1.6	35
369	AÎ² peptide1â€“42, Tau protein and S-100B protein level in cerebrospinal fluid of three patients with primary progressive aphasia. Neuroscience Letters, 2002, 333, 33-36.	1.0	14
370	Highly conserved and disease-specific patterns of carboxyterminally truncated AÎ² peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. Journal of Neurochemistry, 2002, 81, 481-496.	2.1	240
371	Isoform Pattern of 14-3-3 Proteins in the Cerebrospinal Fluid of Patients with Creutzfeldt-Jakob Disease. Journal of Neurochemistry, 2002, 73, 2485-2490.	2.1	92
372	Decreased CSF amyloid Î²42 and normal tau levels in dementia with Lewy bodies. Neurology, 2001, 56, 576-576.	1.5	30
373	Unaltered apoptotic behaviour of mononuclear cells from patients with sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2001, 248, 690-694.	1.8	1
374	Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Annals of Neurology, 2001, 50, 150-156.	2.8	229
375	Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software. Clinical Chemistry and Laboratory Medicine, 2001, 39, 324-32.	1.4	65
376	Creutzfeldt-Jakob disease and oxidative stress. Acta Neurologica Scandinavica, 2000, 101, 332-334.	1.0	18
377	Decreased Î²-amyloid ₁₋₄₂ in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology, 2000, 54, 1099-1102.	1.5	182
378	Boxing and Running Lead to a Rise in Serum Levels of S-100B Protein. International Journal of Sports Medicine, 2000, 21, 551-555.	0.8	113

#	Article	IF	Citations
379	Clinical and differential diagnosis of Creutzfeldt-Jakob disease. , 2000, , 153-159.		11
380	Late Increase of Serum S100 Î² Protein Levels in Hamsters after Oral or Intraperitoneal Infection with Scrapie. Journal of Infectious Diseases, 1999, 180, 518-520.	1.9	9
381	Cisternal S100 protein and neuron-specific enolase are elevated and site-specific markers in intractable temporal lobe epilepsy. Epilepsy Research, 1999, 36, 75-82.	0.8	68
382	Kinetics of Serum Neuron-Specific Enolase and Prolactin in Patients After Single Epileptic Seizures. Epilepsia, 1999, 40, 713-718.	2.6	43
383	Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metabolic Brain Disease, 1999, 14, 239-251.	1.4	28
384	Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Annals of Neurology, 1998, 43, 32-40.	2.8	456
385	Decrease of S100 beta protein in serum of patients with amyotrophic lateral sclerosis. Neuroscience Letters, 1998, 240, 171-173.	1.0	35
386	Elevated levels of serum SlOO beta protein in scrapie hamsters. Journal of NeuroVirology, 1998, 4, 572-573.	1.0	9
387	Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study. BMJ: British Medical Journal, 1998, 316, 577-582.	2.4	94
388	Diagnosis of Creutzfeldt-Jakob disease and related human spongiform encephalopathies. Biomedicine and Pharmacotherapy, 1997, 51, 381-387.	2.5	41
389	Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldtâ€“Jakob disease. Neuroscience Letters, 1997, 225, 210-212.	1.0	332
390	S-100 protein concentration in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Journal of Neurology, 1997, 244, 566-570.	1.8	118
391	Diagnosis of Creutzfeldt-Jakob disease by two-dimensional gel electrophoresis of cerebrospinal fluid. Lancet, The, 1996, 348, 846-849.	6.3	103
392	Clinical implications of nucleic acid amplification methods for the diagnosis of viral infections of the nervous system. Journal of NeuroVirology, 1996, 2, 175-190.	1.0	55
393	Focal blockade of single unit synaptic transmission by iontophoresis of antagonists. NeuroReport, 1991, 2, 185-188.	0.6	7